First Author: G.Martone ITALY
Co Author(s): C. Traversi E. Nuti P. Pichierri A. Tarantello 0 0 0 0 0 0 0 0 0
Back to previous
To analyse the effect of resveratrol and ranibizumab therapy on subfoveal choroidal thickness (SFCT) in patients with diabetic macular edema (DME) using spectral-domain optical coherence tomography (SD-OCT).
Ophthalmology Department, University of Siena, Italy
This prospective study evaluated the mean SFCT before and at 6 months after resveratrol treatment in 12 eyes treated also with ranibizumab injections for diabetic macular edema. Enhanced depth imaging optical coherence tomography (EDI-OCT) was performed to measure SFCT .
Mean SFCT was 338.5 μm and 277.4 μm before and at 6 months after treatment, respectively. OCT measurements showed a significant decrease in the mean SFCT after treatment at 6 months follow-up (p=.03). The mean number of injections was 4.1±0.8.
Diabetic eyes with macular edema treated with resveratrol and ranibizumab showed a decrease of SFCT. The choroidal thickness decreased after treatment, suggesting after this treatment could be an improvement of anti-angiogenic and anti-inflammatory effect suggesting for a reduced choroidal vascular permeability.